MaaT Pharma Presents Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big data analysis platform, GutPrint.